MX343801B - Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. - Google Patents
Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.Info
- Publication number
- MX343801B MX343801B MX2013000673A MX2013000673A MX343801B MX 343801 B MX343801 B MX 343801B MX 2013000673 A MX2013000673 A MX 2013000673A MX 2013000673 A MX2013000673 A MX 2013000673A MX 343801 B MX343801 B MX 343801B
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- blood plasma
- expression level
- treatment
- metastatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a métodos para mejorar el efecto de tratamiento de un régimen de quimioterapia de un paciente que sufre cáncer de mama, en particular cáncer de mama negativo HER-2 localmente avanzado, recurrente o metastásico, al agregar bevacizumab (Avastin(r)) a un régimen de quimioterapia, al determinar el nivel de expresión, en particular el nivel de expresión en plasma de sangre, de uno o más de VEGFA, VEGFR2 y PLGF respecto a niveles de control de pacientes diagnosticados con cáncer de mama, en particular cáncer de mama negativo HER-2 localmente avanzado, recurrente o metastásico. En particular, la presente invención proporciona métodos para mejorar el efecto de tratamiento, en donde el efecto de tratamiento es la supervivencia libre de progreso del paciente. La presente invención además proporciona métodos para estimar la sensibilidad o respuesta de un paciente a bevacizumab (Avastin(r)) en combinación con un régimen de quimioterapia, al determinar el nivel de expresión, en particular el nivel de expresión en plasma de sangre, de uno o más de VEGFA, VEGFR2 y PLGF respecto a niveles de control en pacientes con diagnóstico de cáncer de mama, en particular cáncer de mama negativo HER-2 localmente avanzado, recurrente o metastásico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10170008 | 2010-07-19 | ||
| PCT/EP2011/062232 WO2012010552A1 (en) | 2010-07-19 | 2011-07-18 | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013000673A MX2013000673A (es) | 2013-02-27 |
| MX343801B true MX343801B (es) | 2016-11-23 |
Family
ID=44545675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013000673A MX343801B (es) | 2010-07-19 | 2011-07-18 | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20130121999A1 (es) |
| EP (2) | EP2596363B1 (es) |
| JP (1) | JP6055764B2 (es) |
| KR (1) | KR20130091750A (es) |
| CN (2) | CN105327347A (es) |
| AU (1) | AU2011281706A1 (es) |
| BR (1) | BR112013001423A2 (es) |
| CA (1) | CA2804350A1 (es) |
| ES (1) | ES2619590T3 (es) |
| HK (2) | HK1184854A1 (es) |
| MX (1) | MX343801B (es) |
| NZ (1) | NZ603780A (es) |
| RU (1) | RU2013106938A (es) |
| SG (1) | SG187013A1 (es) |
| WO (1) | WO2012010552A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011205343B2 (en) | 2010-01-12 | 2015-08-13 | Nestec S.A. | Methods for predicting response of triple-negative breast cancer to therapy |
| EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| AU2012348600A1 (en) * | 2011-12-05 | 2014-05-22 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| US9116159B2 (en) | 2012-05-22 | 2015-08-25 | Regeneron Pharmaceuticals, Inc. | VEGF-A121 assay |
| IL302218B1 (en) | 2014-08-28 | 2024-06-01 | Eisai R&D Man Co Ltd | Methods for the production of lanvotinib and its derivatives in a high degree of purity |
| EP3204516B1 (en) | 2014-10-06 | 2023-04-26 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| CA2968352A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
| DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| EP3311841B1 (en) | 2015-06-16 | 2021-07-28 | PRISM BioLab Co., Ltd. | Anticancer agent |
| WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| CN110753755B (zh) | 2016-03-21 | 2023-12-29 | 丹娜法伯癌症研究院 | T细胞耗竭状态特异性基因表达调节子及其用途 |
| US9950070B2 (en) | 2016-08-16 | 2018-04-24 | Korea University Research And Business Foundation | HER2 aptamer-anticancer drug complex for cancer cell chemotherapy |
| KR102247908B1 (ko) | 2020-10-08 | 2021-05-06 | 주식회사 엠디엡투스 | Her2 압타머-항암 약물 복합체 및 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19806989A1 (de) | 1998-02-19 | 1999-08-26 | Roche Diagnostics Gmbh | Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays |
| AU2003265294B8 (en) * | 2002-07-19 | 2009-06-25 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| DE102004029909A1 (de) | 2004-06-21 | 2006-01-19 | Roche Diagnostics Gmbh | Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern |
| CN101068561A (zh) * | 2004-10-06 | 2007-11-07 | 蒂尔坦制药有限公司 | 用于加强抗血管生成疗法的方法和组合物 |
| CN101454668A (zh) * | 2005-11-14 | 2009-06-10 | 拜耳医药保健有限责任公司 | 癌症预测与预后以及监测癌症治疗的方法 |
| PT2117520T (pt) * | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
| AU2008205543A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
| ZA200904860B (en) * | 2007-02-01 | 2010-09-29 | Genentech Inc | Combination therapy with angiogenesis inhibitors |
| EP2065399A1 (en) * | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy |
| US10031141B2 (en) * | 2007-11-30 | 2018-07-24 | Genentech, Inc. | VEGF polymorphisms and anti-angiogenesis therapy |
| US20100004306A1 (en) * | 2008-06-18 | 2010-01-07 | Abbott Laboratories | PIGF-1 Assay and kits and components thereof |
| KR20140020368A (ko) * | 2008-12-23 | 2014-02-18 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
-
2011
- 2011-07-18 CN CN201510684543.4A patent/CN105327347A/zh active Pending
- 2011-07-18 EP EP11746191.3A patent/EP2596363B1/en active Active
- 2011-07-18 CA CA2804350A patent/CA2804350A1/en not_active Abandoned
- 2011-07-18 AU AU2011281706A patent/AU2011281706A1/en not_active Abandoned
- 2011-07-18 KR KR1020137004172A patent/KR20130091750A/ko not_active Application Discontinuation
- 2011-07-18 RU RU2013106938/15A patent/RU2013106938A/ru not_active Application Discontinuation
- 2011-07-18 EP EP16184951.8A patent/EP3156800A1/en not_active Withdrawn
- 2011-07-18 WO PCT/EP2011/062232 patent/WO2012010552A1/en active Application Filing
- 2011-07-18 SG SG2013001946A patent/SG187013A1/en unknown
- 2011-07-18 ES ES11746191.3T patent/ES2619590T3/es active Active
- 2011-07-18 NZ NZ60378011A patent/NZ603780A/en not_active IP Right Cessation
- 2011-07-18 JP JP2013520106A patent/JP6055764B2/ja not_active Expired - Fee Related
- 2011-07-18 CN CN201180044840.2A patent/CN103109188B/zh not_active Expired - Fee Related
- 2011-07-18 MX MX2013000673A patent/MX343801B/es active IP Right Grant
- 2011-07-18 BR BR112013001423A patent/BR112013001423A2/pt not_active IP Right Cessation
-
2012
- 2012-12-27 US US13/728,411 patent/US20130121999A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/801,923 patent/US20130183303A1/en not_active Abandoned
- 2013-03-13 US US13/801,914 patent/US20130183302A1/en not_active Abandoned
- 2013-10-30 HK HK13112206.0A patent/HK1184854A1/zh not_active IP Right Cessation
- 2013-10-30 HK HK16105145.5A patent/HK1217093A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6055764B2 (ja) | 2016-12-27 |
| US20130121999A1 (en) | 2013-05-16 |
| CN103109188A (zh) | 2013-05-15 |
| AU2011281706A1 (en) | 2013-01-10 |
| CA2804350A1 (en) | 2012-01-26 |
| ES2619590T3 (es) | 2017-06-26 |
| HK1184854A1 (zh) | 2014-01-30 |
| US20130183303A1 (en) | 2013-07-18 |
| JP2013534308A (ja) | 2013-09-02 |
| RU2013106938A (ru) | 2014-08-27 |
| US20130183302A1 (en) | 2013-07-18 |
| NZ603780A (en) | 2015-04-24 |
| KR20130091750A (ko) | 2013-08-19 |
| HK1217093A1 (zh) | 2016-12-23 |
| SG187013A1 (en) | 2013-02-28 |
| WO2012010552A1 (en) | 2012-01-26 |
| EP2596363A1 (en) | 2013-05-29 |
| CN105327347A (zh) | 2016-02-17 |
| EP3156800A1 (en) | 2017-04-19 |
| EP2596363B1 (en) | 2017-01-18 |
| CN103109188B (zh) | 2015-11-25 |
| MX2013000673A (es) | 2013-02-27 |
| BR112013001423A2 (pt) | 2016-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX343801B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. | |
| MX339427B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico. | |
| MX2012007940A (es) | Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab. | |
| AR089067A1 (es) | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama | |
| PH12021550758A1 (en) | The use of inhibitors of bruton`s tyrosine kinase (btk) | |
| MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| MX2014000292A (es) | Usos de inhibidores etiquetados hsp90. | |
| NZ607282A (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| GB201015765D0 (en) | Use of myeloid cell biomarkers for the diagnosis of cancer | |
| WO2013153458A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| NZ601348A (en) | Methods for predicting response of triple-negative breast cancer to therapy | |
| NZ701652A (en) | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression | |
| WO2012109632A3 (en) | Crown-like structures as a biomarker for cancer risk and cancer prognosis | |
| WO2010116003A3 (en) | Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy | |
| WO2011153345A3 (en) | A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients | |
| WO2010115997A3 (en) | Method for determining survival prognosis of patients suffering from non-small cell lung cancer (nsclc) | |
| WO2012138691A3 (en) | Diagnosis and treatment of taxane-resistant cancers | |
| WO2010093450A3 (en) | Pten phosphorylation-driven restistance to cancer treatment and altered prognosis | |
| MX2014014821A (es) | Biomarcadores de plasma sanguineo para terapias de combinacion con bevacizumab para el tratamiento de cancer de mama. | |
| EA201501095A1 (ru) | Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли | |
| WO2011011453A3 (en) | Phenotyping tumor-infiltrating leukocytes | |
| MX2013013153A (es) | La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon. | |
| UA84044U (ru) | Способ прогнозирования чувствительности к неоадьювантной терапии у больных раком молочной железы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |